<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434627</url>
  </required_header>
  <id_info>
    <org_study_id>Pro35228</org_study_id>
    <nct_id>NCT02434627</nct_id>
  </id_info>
  <brief_title>Sodium Nitrate for Muscular Dystrophy</brief_title>
  <official_title>Sodium Nitrate for Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' previous work in males with Becker Muscular Dystrophy shows that
      functional sympatholysis is restored by acute inorganic nitrate supplementation. This was
      translated from work using the mdx mouse model of dystrophinopathy. Recent work has shown
      that there is a frank improvement in grip strength when mdx mice are treated with an
      inorganic Nitric Oxide (NO) donor. The purpose of this study is to determine if chronic
      treatment with an inorganic NO donor can benefit patients with muscular dystrophy beyond
      blood flow regulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maximal handgrip strength</measure>
    <time_frame>Change from baseline in handgrip strength at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function - Performance of Upper Limb Scale</measure>
    <time_frame>Change from baseline in muscle function - the Performance of Upper Limb Scale at 3 months</time_frame>
    <description>Change in functional muscle assessment as measured by the Performance of Upper Limb Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle tissue markers - histology and proteomics</measure>
    <time_frame>Change from baseline in muscle tissue markers at 3 monthss</time_frame>
    <description>Change in tissue markers such as neuronal Nitric Oxide Synthase (nNOS) content and location and nitrosative stress by histology and proteomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic wall strain - imaging</measure>
    <time_frame>Change from baseline in cardiac systolic wall strain at 3 months</time_frame>
    <description>Change in the cardiac wall strain as measured by Cardiac Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function - North Star Ambulatory Assessment</measure>
    <time_frame>Change from baseline in muscle function - North Star Ambulatory Assessment at 3 months</time_frame>
    <description>Change in functional muscle assessment as measured by the North Star Ambulatory Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function - 6 minute walk test</measure>
    <time_frame>Change from baseline in muscle function - 6 minute walk test at 3 months</time_frame>
    <description>Change in functional muscle assessment as measured by the 6 minute walk test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Sodium Nitrate (Beetroot Juice)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrate</intervention_name>
    <description>Patients will be given sodium nitrate daily in the form of beetroot juice.</description>
    <arm_group_label>Sodium Nitrate (Beetroot Juice)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of muscular dystrophy

          -  Age 15-45 years of age

          -  Ambulatory

          -  No clinical evidence of heart failure

          -  Maximum voluntary contraction, measured by hand grip dynamometer, of 20-40 kg

        Exclusion Criteria:

          -  Hypertension, diabetes, or heart failure by standard clinical criteria

          -  Elevated B-type Natruiretic Peptide level (&gt;100 pg/ml)

          -  Left Ventricular Ejection Fraction &lt; 50%

          -  Wheelchair bound

          -  Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular
             Tachycardia, atrial fibrillation, ventricular tachycardia

          -  Continuous ventilatory support

          -  Liver disease

          -  Renal impairment

          -  Contraindications to NO donors (use of nitrates, alpha-blockers, CYP3A inhibitors,
             amlodipine, or Phosphodiesterase type 5 (PDE5) inhibitors) Glucocorticoid therapy and
             prophylactic use of Angiotensin Converting Enzyme (ACE) inhibitors and beta-blockers
             for cardiac protection will not be exclusion criteria.

          -  Maximum voluntary contraction of less than 20 kg or greater than 40 kg

          -  Ventilation Devices (Continuous Positive Airway Pressure (CPAP), Bilevel Positive
             Airway Pressure (BiPAP))
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald G Victor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Rashid</last_name>
    <email>Mohamad.Rashid@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Rashid, CCRC</last_name>
      <phone>424-315-2501</phone>
      <email>Mohamad.Rashid@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Hakimi, MD</last_name>
      <phone>310.967.3848</phone>
      <email>Matthew.Hakimi@cshs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Ron Victor</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Becker</keyword>
  <keyword>Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

